AI breast-cancer detection tools underperform radiologists' expectations

A survey of 215 members of the Society of Breast Imaging found about half already use FDA-approved AI tools for breast cancer detection. Only 35% reported lower recall rates, well below the 59% who had expected that benefit, with similar gaps across other measured categories.

Why it matters: This is a real-world reality check on clinical AI adoption: FDA clearance and hospital deployment don't guarantee the improvement clinicians were promised. It's a useful data point for anyone gauging how fast diagnostic AI is actually paying off versus how fast it's being purchased.